Table 4.
Safety outcomes for the included studies
| First Author | Groups | Patients with ≥ 1 TEAE, n (%) | Grade ≥ 3 TEAEs, n (%) | Serious TEAEs, n (%) | TEAEs leading to death, n (%) | TEAEs leading to discontinuation, n (%) | TEAEs leading to dose modification or treatment delays, n (%) |
|---|---|---|---|---|---|---|---|
| Li et al. 2022 [18] |
TS + CT CT |
N/A N/A |
N/A N/A |
N/A N/A |
N/A N/A |
N/A N/A |
N/A N/A |
| Lu et al. 2021 [19] |
TS + CT CT |
222 (100) 109 (99.1) |
150 (67.6) 59 (53.6) |
74 (33.3) 23 (20.9) |
7 (3.2) 2 (1.8) |
57 (25.7) 10 (9.1) |
149 (67.1) 57 (51.8) |
| Wang et al. 2021 [20] |
Arm A: TS + CT (PTX + CBP) Arm B: TS + CT (nab PTX + CBP) Arm C: CT (PTX + CBP) |
120 (100.0) 117 (99.2) 117 (100.0) |
106 (88.3) 102 (86.4) 98 (83.8) |
44 (36.7) 45 (38.1) 29 (24.8) |
4 (3.3) 5 (4.2) 5 (4.3) |
15 (12.5) 35 (29.7) 18 (15.4) |
N/A N/A N/A |
| Zhou et al. 2022 [21] |
TS CT |
517 (96.8) 254 (98.4) |
225 (42.1) 193 (74.8) |
184 (34.5) 84 (32.6) |
34 (6.4) 12 (4.7) |
64 (12.0) 34 (13.2) |
125 (23.4) 96 (37.2) |
Abbreviations: TEAE: treatment-emergent adverse event; TS: tislelizumab; CT: chemotherapy; PTX: paclitaxel; CBP: carboplatin; N/A: not available